Sun Pharma rises on receiving EIR from USFDA for Dadra facility

12 Oct 2017 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 538.40, up by 12.60 points or 2.40% from its previous closing of Rs. 525.80 on the BSE.

The scrip opened at Rs. 544.20 and has touched a high and low of Rs. 548.00 and Rs. 537.50 respectively. So far 1,56,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 759.00 on 19-Oct-2016 and a 52 week low of Rs. 433.15 on 14-Aug-2017.

Last one week high and low of the scrip stood at Rs. 548.00 and Rs. 516.00 respectively. The current market cap of the company is Rs. 1,29,159.00 crore.

The promoters holding in the company stood at 54.38%, while Institutions and Non-Institutions held 32.60% and 13.01% respectively.

Sun Pharmaceutical Industries has received an Establishment Inspection Report (EIR) from the US Food Drug and Administration (USFDA) in respect of Dadra facility based upon the company’s responses to the observation letter.

EIR is issued to the entity when the USFDA concludes that an inspection is closed under Title 21 Section 20.64 (d) (3) of Code of Federal Regulation.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.


Sun Pharma Inds. Share Price

1795.30 -9.65 (-0.53%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×